Having experienced multiple hemorrhagic events from dual antiplatelet therapy including Xarelto after a 100% LAD arterial blockage STEMI with residual intracardiac thrombosis, it seems to me that the problem is one where patients are simply not monitored closely enough.
By the third ER visit for bleeding with the physician deferring to th…
Having experienced multiple hemorrhagic events from dual antiplatelet therapy including Xarelto after a 100% LAD arterial blockage STEMI with residual intracardiac thrombosis, it seems to me that the problem is one where patients are simply not monitored closely enough.
By the third ER visit for bleeding with the physician deferring to the Cardiologist's "do not stop the regimen," but refusing to order even so much as an echocardiogram to see if the clot had dissolved (EF of 45% on initial post-STEMI hospital discharge and clot dissolved approximately 75%,) I see this issue as being intractable.
Having experienced multiple hemorrhagic events from dual antiplatelet therapy including Xarelto after a 100% LAD arterial blockage STEMI with residual intracardiac thrombosis, it seems to me that the problem is one where patients are simply not monitored closely enough.
By the third ER visit for bleeding with the physician deferring to the Cardiologist's "do not stop the regimen," but refusing to order even so much as an echocardiogram to see if the clot had dissolved (EF of 45% on initial post-STEMI hospital discharge and clot dissolved approximately 75%,) I see this issue as being intractable.